Drug intelligence / Profile preview

heliox21

Development stage
Phase 4
Lead developer
Linde
Modality
Small Molecules
Administration
Inhalation
01

Overview

Heliox21 is a medical gas mixture composed of 79% helium and 21% oxygen. It is utilized in respiratory therapy to reduce the work of breathing (WOB) in patients with airway obstruction or those requiring ventilatory support, such as post-extubation patients in the intensive care unit. The therapeutic rationale for Heliox21 is based on the physical properties of helium; being significantly less dense than nitrogen (the primary component of atmospheric air), the mixture reduces the Reynolds number of the gas flow, thereby promoting laminar flow and decreasing airway resistance. This facilitates more efficient gas delivery to the distal alveoli and reduces the pressure required to move gas through narrowed airways. In clinical practice, it is often administered via non-invasive ventilation (NIV) to prevent respiratory failure and ease the transition from mechanical ventilation.

Brand names
Heliox21Heliox-21Heliox 21
Other names
Heliox 21Heliox21Heliox-21Helium-oxygen 79/21He-O2 79/21

Beyond the preview

Go deeper on heliox21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on heliox21.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call